Wednesday, July 15, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

Analysis of recent national trends in Medicaid and CHIP enrollment

This data note looks at national and state-by-state Medicaid and CHIP enrollment data through April 2021, as the vaccine was becoming more available to the general public. After declines in enrollment from 2017 through 2019, total Medicaid/CHIP enrollment grew to 82.3 million in April 2021, an increase of 11.1 million from enrollment in February 2020 (15.5%), right before the pandemic and when enrollment began to steadily increase.

Increases in enrollment reflect changes in the economy (as more people experience income and job loss and become eligible and enroll in Medicaid and CHIP coverage) and provisions in the Families First Coronavirus Response Act (FFCRA) that require states to ensure continuous coverage to current Medicaid enrollees to access a temporary increase in the Medicaid match rates. While enrollment has increased for 14 consecutive months, the monthly increases appear to be slowing compared to April through August 2020, when monthly increases were the largest. However, continued economic uncertainty and fallout from the more transmissible delta variant could impact future Medicaid enrollment trends.

Source: Kaiser Family Foundation

Analysis of National Trends in Medicaid and CHIP Enrollment During the COVID-19 Pandemic

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!